KBC Securities - MAAT PHARMA SA (MAAT) MaaT Pharma Business update and milestones ahead

Report

KBC Securities

Jacob Mekhael ...

Thomas Vranken

MaaT Pharma Business update and milestones ahead

MaaT Pharma provides a broad overview of its recent activities and expected milestones. We can expect a number of updates from MaaT's pipeline in the coming months, the most notable of which is the primary endpoint readout (28 day GI-ORR) from the Ph3 ARES trial of enema MaaT013 in aGvHD, which is expected mid 4Q24. We reiterate our € 15 TP and Buy rating.

08/05/2024 1 EN

Underlying

MAAT PHARMA SA

See profile

FR0012634822 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Thomas Vranken

Other Reports on these Companies

KBC Securities

Morning Notes : ABN NA, ENX FP, HOMI BB, MONT BB, MAAT FP

: ABN NA, ENX FP, HOMI BB, MONT BB, MAAT FP

May 15, 2024 May 15, 2024 1 EN

KBC Securities

MaaT Pharma Secures 19m via global offering, extends runway to 1Q25

MaaT completed a global offering (reserved offering and primary bid offering) of approx. 2.3m new ordinary shares at a price of € 8 per share (discount of approx. 14% vs. last close) for gross proceeds of € 19.2m (net proceeds € 17.3m). The funds lift the financing overhang for MaaT and extend the company's runway to early 1Q25 (previously end 3Q24). This provides funding beyond the topline readout (ORR) from the phase 3 (ARES) trial of MaaT013 in aGvHD expected in mid 4Q24, which we view as the next trigger for the stock. We update our model for the additional cash and dilution, and land at a...

May 15, 2024 May 15, 2024 1 EN

BusinessWire

MaaT Pharma annonce le succès de son Offre Globale de 19,2 millions d’euros

LYON, France--(BUSINESS WIRE)-- Regulatory News: CE COMMUNIQUE ET LES INFORMATIONS QU’IL CONTIENT SONT RESTREINTS ET NE SONT PAS DESTINES A LA DIFFUSION, A LA PUBLICATION OU A LA DISTRIBUTION, EN TOUT OU PARTIE, DIRECTEMENT OU INDIRECTEMENT, EN AUSTRALIE, AU CANADA, AU JAPON, EN AFRIQUE DU SUD OU AUX ETATS-UNIS OU DANS TOUT AUTRE JURIDICTION DANS LAQUELLE UNE TELLE DIFFUSION, PUBLICATION OU DISTRIBUTION SERAIT ILLEGALE. CE COMMUNIQUE EST ETABLI A TITRE D’INFORMATION UNIQUEMENT ET NE CONSTITUE PAS, NI NE CONTIENT AUCUNE INVITATION, SOLLICITATION, RECOMMANDATION, OFFRE OU CONSEIL A QUICONQUE...

May 15, 2024 May 15, 2024 1 FR

Autolus 1Q24 update reiterates pipeline timelines, obe-cel data at ASCO

Autolus reported uneventful 1Q24 results, with a cash position of $758.5m (FY23: $ 239.6m), sufficient to fund the company into the first pivotal data from obe-cel (CD19 CAR-T) in autoimmune disease (we expect this to come in 2027/2028). The company reiterated pipeline timelines, with the next key event being additional analysis and longer follow up from the phase 2 (FELIX) trial of obe-cel in r/r adult ALL, expected at ASCO in June 2024, which will provide more insight into long term durability. We reiterate our $ 11 TP and BUY rating. Autolus is one of our life sciences top picks.

May 17, 2024 May 17, 2024 1 EN

Guy Sips ... (+6)

Guy Sips
Hilde Van Boxstael
Jacob Mekhael
Kristof Samoy
Sharad Kumar S.P
Wim Lewi

Morning Notes : EVS BB, EXM BB, HAL NA, IVA FP, XIOR BB, NXFIL NA

: EVS BB, EXM BB, HAL NA, IVA FP, XIOR BB, NXFIL NA

May 17, 2024 May 17, 2024 1 EN

Guy Sips

Guy Sips

EVS Broadcast Equipment The pipeline looks promising to ensure a strong FY24

EVS started FY24 with a strong 1Q24, despite the reserved production capacity dedicated to this years Big Events (Olympics, EK). We welcome EVS indicated that at the same time the pipeline looks promising to ensure a strong FY24. EVS reiterated its revenue guidance of €180m to € 195m (KBCSe € 189.2m) and now expects FY24 EBIT to land between € 38.0m and € 45.0m (KBCSe € 43.6m). We maintain our Buy but increased our Target Price from € 37.5 to € 39, in line with our updated DCF.

May 17, 2024 May 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MaaT Pharma Business update and milestones ahead

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : ABN NA, ENX FP, HOMI BB, MONT BB, MAAT FP

MaaT Pharma Secures 19m via global offering, extends runway to 1Q25

MaaT Pharma annonce le succès de son Offre Globale de 19,2 millions d’euros

Autolus 1Q24 update reiterates pipeline timelines, obe-cel data at ASCO

Morning Notes : EVS BB, EXM BB, HAL NA, IVA FP, XIOR BB, NXFIL NA

EVS Broadcast Equipment The pipeline looks promising to ensure a strong FY24

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe